Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
What has changed in AML treatment in the last 30 years?
Mohamad Mohty on EBMT 2016
Challenges with measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Drugs vs transplants in acute leukemias